MedTrace Logo

The Influence of Glutamate on Memory in Humans

NCT00980408 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2014-12-03

No results posted yet for this study

Summary

The hippocampus is particularly laden with n-methyl-d-aspartate (NMDA) receptors, and is at the same time one of the most important sites in declarative memory. The rationale of this study is that the NMDA partial agonist D-Cycloserine will promote learning compared to a placebo. On the other hand, the NMDA receptor antagonist Memantine might lead to reduced memory. We believe that the influence of NMDA receptors on memory can be determined via acute co-activation of the NMDA receptors with Cycloserine® (King Pharmaceuticals Ltd, active ingredient: DCycloserin, dose: 250 mg) and Memantine (Axura®, Merz, active ingredient: Memantine, dose: 20 mg)on both a behavioral and functional (fMRI) level.

Conditions

  • Healthy Individuals

Interventions

DRUG

Sugar pill

250 mg, one dose, 60 min prior

DRUG

Sugar pill

250 mg, one dose, 60 min prior

DRUG

Sugar pill

20 mg, one dose, 8 hours prior

DRUG

Sugar pill

20 mg, one dose, 8 hours prior

DRUG

Glutamic Acid

250 mg, one dose, 60 minutes prior

DRUG

Glutamic Acid

250 mg, one dose, 60 minutes prior

DRUG

Memantine

20 mg, one dose, 8 hours prior

DRUG

Memantine

20 mg, one dose, 8 hours prior

Sponsors & Collaborators

  • University Hospital, Bonn

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00980408 on ClinicalTrials.gov